Abstract Number: PB2543
Meeting: ISTH 2020 Congress
Background: As it is known the pregnancy loss is a marker and the most striking manifestation of antiphospholipid syndrome (APS). Pregnant women with antiphospholipid antibodies (aPL) circulation has a potential risk of placental insufficiency and fetal growth restriction development.
Aims: The evaluation of aPL profile in patients with recurrent pregnancy loss.
Methods: 146 women with history of recurrent miscarriage and 60 age matched healthy pregnant women were examined for anticardiolipin (aCL), anti-annexin V, anti-b2-GPI, anti-prothrombin (aPt) antibodies and LA circulation. Of them, 74 women were in the I trimester of pregnancy and 72 admitted in II and III trimesters.
Results: 34,2% women were diagnosed APS. LA circulation – 14%, anticardiolipin – 31,5%, anti-annexin V – 31%, anti-b2-GPI – 22,6, anti-prothrombin – 10,3%. Combination of LA, anti-b2-GPI, anticardiolipin was in 12,1%, LA, anti-annexin V and anti-b2-GPI – in 13,7%, anti-prothrombin and anti-b2-GP I – in 8,9%, LA, annexin V and b2-GPI – in 7,9% and was associated with more severe complications. All patients received anticoagulant therapy with nadroparin calcium. In women treated before the pregnancy early miscarriage in the next pregnancy occurred in 1,6%. There was no antenatal death or stillbirth. In women started the therapy in II or III trimesters the frequency of obstetric complications was higher (p< 0.05) but still significantly lower compared with their history without therapy.
Conclusions: 34% fetal loss cases were associated with antiphospholipid syndrome. The combination of various antibodies at the same time in women with more severe obstetric history demonstrates the diagnostic value of the determination of different groups of aPL. LMWH (nadroparin calcium) was effective for prevention of recurrent thromboembolism and obstetric complication.
To cite this abstract in AMA style:Bitsadze V, Khizroeva J, Orudzhova E, Shkoda A, Bayanduryan E, Novosartyan M, Makatsariya A. Antithrombotic Therapy (Nadroparin Calcium) in the Prevention of Pregnancy Loss in aPL-Positive Women [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/antithrombotic-therapy-nadroparin-calcium-in-the-prevention-of-pregnancy-loss-in-apl-positive-women/. Accessed January 26, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/antithrombotic-therapy-nadroparin-calcium-in-the-prevention-of-pregnancy-loss-in-apl-positive-women/